Monoclonal Antibody Or Fragment Thereof (i.e., Produced By Any Cloning Technology) Patents (Class 424/141.1)
  • Patent number: 11370826
    Abstract: The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: June 28, 2022
    Assignee: Bracco Suisse SA
    Inventors: Federico Maisano, Federico Crivellin, Thierry Bettinger, Philippe Bussat, Samir Cherkaoui, Christian Koller, Adrian Lobito
  • Patent number: 11357851
    Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment. In particular, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: June 14, 2022
    Assignee: Novartis AG
    Inventors: Shinji Hatakeyama, Ronenn Roubenoff, Estelle Trifilieff, Jerome Feige, Lloyd B. Klickstein
  • Patent number: 11357823
    Abstract: The invention relates to the field of biomedicine, in particular to the use of annexin A5 in the treatment of cerebral stroke. The invention provides a method for treating cerebral stroke and a drug combination containing annexin A5. The method can reduce cerebral infarction, improve symptoms of neurobehavioral deficits in the brain and treating stroke.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: June 14, 2022
    Assignee: SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD
    Inventors: Lei Yang, Guoning Lian, Xiaoping Gao, Lin Zhu
  • Patent number: 11273217
    Abstract: Mesothelioma growth inhibitory effect of standard cisplatin-pemetrexed concomitant therapy is potentiated by combination with an anti-CD26 antibody. A high therapeutic effect and excellent safety is obtained by the concomitant use of an anti-CD26 antibody and gemcitabine. By conjugating an anti-CD26 antibody (YS110) with triptolide via a divalent cross-linking agent for concomitant therapy using the anti-CD26 antibody, a novel antibody-drug conjugate (Y-TR1) very highly effective for CD26-positive malignant mesothelioma cells has been successfully obtained.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 15, 2022
    Assignee: Y's AC Co., Ltd.
    Inventors: Taketo Yamada, Mutsumi Hayashi, Kohji Yamada, Chikao Morimoto, Toshihiro Okamoto, Yutaro Kaneko
  • Patent number: 11267900
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: March 8, 2022
    Assignees: Daiichi Sankyo Europe GmbH, Amgen Inc.
    Inventors: Mike Rothe, Martin Treder, Eric Borges, Larry L. Green, Susanne Hartmann
  • Patent number: 11246923
    Abstract: The present invention discloses processes for producing native, depigmented and polymerised allergen extracts. The invention further discloses extracts produced via the processes, and pharmaceutical and vaccine compositions comprising the extracts, for diagnosis and treatment of allergy.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: February 15, 2022
    Assignee: Laboratorios Leti, S.L. Unipersonal
    Inventor: Jeronimo Carnes Sanchez
  • Patent number: 11210341
    Abstract: Systems and methods are disclosed for optimizing responses to queries. Analyses of user interactions and other behaviors can lead to association of queries with signals, including ASINs and other product descriptions. The associations can be algorithmically graphed and analyzed on a disaggregated basis and individually weighted to improve search recall and reduce the risk of returning defective search results. Machine learning techniques can further optimize the associations and/or the search results.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: December 28, 2021
    Assignee: A9.com, Inc.
    Inventor: Rahul Bhagat
  • Patent number: 11203633
    Abstract: This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind to Pseudomonas PcrV as well as vectors and host cells comprising the same.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: December 21, 2021
    Assignee: MedImmune Limited
    Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha S. Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainey, Cuihua Gao
  • Patent number: 11173208
    Abstract: The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least 20 mg/ml, a tonicity modifier, a buffer and one or more of surfactants, amino acids, antioxidants and/or chelators, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: November 16, 2021
    Assignee: Takeda GmbH
    Inventors: Willow Diluzio, Phuong Nguyen
  • Patent number: 11167007
    Abstract: Disclosed herein, inter alia, are FOXM1 modulators and methods for modulating the activity of androgen receptors in neuronal cells to treat various diseases, such as spinal-bulbar muscular atrophy, amyotrophic lateral sclerosis, and Alzheimer's disease.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: November 9, 2021
    Assignee: CITY OF HOPE
    Inventors: Jeremy Jones, Maya Otto-Duessel
  • Patent number: 11161911
    Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: November 2, 2021
    Assignee: GO Therapeutics, Inc.
    Inventor: Thayer White
  • Patent number: 11104739
    Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 31, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Josephine M. Cardarelli, Daniel E. Lopes de Menezes, Paul D. Ponath, Bingliang Chen, Chin Pan
  • Patent number: 11078297
    Abstract: The invention provides a method and composition for preventing thrombosis and complications associated therewith by targeting Sf2 directly. The invention provides Sf2-deficiency or prophylactic administration of a therapeutic agent, such as a Sf2 antagonist or a Sf2 antibody, markedly reduces thrombus formation that would otherwise be caused due to surgery, immobility, genetic abnormality, cancer, trauma, or other risk factors.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: August 3, 2021
    Assignee: Translational Sciences, Inc.
    Inventor: Guy L. Reed
  • Patent number: 11045529
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: June 29, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Patent number: 11045532
    Abstract: The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 29, 2021
    Assignee: EpiVax, Inc.
    Inventors: Anne De Groot, William Martin, Daniel S. Rivera
  • Patent number: 10987434
    Abstract: Components, for example, nanoparticles for detecting and/or treating one or more active carious lesions or microcavities in teeth of a subject are provided. The component or nanoparticle may comprise a biocompatible and biodegradable polymer (e.g., a starch) bearing at least one cationic region and/or having a net positive charge and thereby capable of associating with one or more active and/or early carious lesions on a tooth in an oral cavity of a subject. The components or nanoparticles are optionally water soluble or dispersible. The components or nanoparticle also comprises an imaging agent (e.g., a fluorophore or dye) bonded to the biocompatible and biodegradable polymer. The component or nanoparticle is thus capable of indicating the presence of one or more active carious lesions when the component or nanoparticle is associated therewith. Oral care compositions comprising such compounds/nanoparticles and methods of making and using the same are also provided.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 27, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, POZNAN UNIVERSITY OF MEDICAL SCIENCES
    Inventors: Joerg Lahann, Sywe-Ren Chang, Brian Clarkson, Nathan A. Jones, Agata Czajka-Jakubowska
  • Patent number: 10934353
    Abstract: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 2, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • Patent number: 10913797
    Abstract: Anti-PD-1 antibodies and uses thereof in treating diseases associated with the PD-1 signaling, such as cancer, infectious diseases such as viral infection or immune related diseases.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 9, 2021
    Assignee: Lyvgen Biopharma Holdings Limited
    Inventors: Jieyi Wang, Liqun Dong, Yaolin Wang
  • Patent number: 10906991
    Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: February 2, 2021
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Rob Aalberse, Marijn Van Der Neut Kolfschote, Paul Parren
  • Patent number: 10882899
    Abstract: An isolated monoclonal antibody or antigen-binding fragment thereof binds to F. tularensis lipopolysaccharide (Ft LPS). The antibody preferably lacks an Fc region or has an impaired Fc-region. The antibody may be formulated into a pharmaceutical composition along with a pharmaceutically acceptable carrier, excipient or diluent. It may be provided in a kit with means for detection of the antibody and instructions for use. A therapeutically effective amount of such an antibody can be used for prophylaxis, treatment or amelioration of Ft infection and for inhibiting Ft uptake by cells in a subject. The antibody can also be used to detect Ft infection. Also disclosed is an isolated nucleic acid molecule encoding the antibody, an expression vector having the isolated nucleic acid molecule, and a host cell transfected with such an expression vector.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: January 5, 2021
    Assignee: THE ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IIBR)
    Inventors: Adva Mechaly, Ofer Cohen, Ohad Mazor
  • Patent number: 10874548
    Abstract: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 29, 2020
    Assignee: ForSight Vision4, Inc.
    Inventors: Eugene de Juan, Jr., Yair Alster, Steven M. Chamow, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Signe Erickson, Blaine Bueche
  • Patent number: 10844115
    Abstract: Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides (e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: November 24, 2020
    Assignee: Genzyme Corporation
    Inventors: Huawei Qiu, Sunghae Park, James Stefano
  • Patent number: 10765690
    Abstract: Disclosed is a TLR4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 8, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Christopher W. Cluff, Hua-Xin Gao
  • Patent number: 10745482
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: August 18, 2020
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Jean Paoli & Irene Calmettes, Universite d' Aix-Marseille, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 10729694
    Abstract: The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apillimod and at least one additional anti-viral agent.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 4, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad
  • Patent number: 10689450
    Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: June 23, 2020
    Assignee: KITE PHARMA, INC
    Inventors: Jed Wiltzius, Ruben Alvarez Rodriguez, Jonathan Belk
  • Patent number: 10689432
    Abstract: Methods are disclosed for preventing and/or treating cardiovascular diseases comprising administering B7x or a derivative of B7x to a patient in need thereof.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: June 23, 2020
    Assignee: Albert Einstein College of Medicine
    Inventors: Xingxing Zang, Hyungjun Jeon
  • Patent number: 10676508
    Abstract: The present invention provides DEPDC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: June 9, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Sachiko Yamashita, Tetsuro Hikichi
  • Patent number: 10656228
    Abstract: A method for determining a change over time in a biomarker in a region to be examined of a patient is provided. The change is determined from magnetic resonance data using a magnetic resonance measuring system with sequences and protocols for measuring the biomarkers by functional resting state connectivity by rsfMRI, perfusion values, magnetic resonance spectra of voxels, or morphometry of organs. A control unit has programs which evaluates the biomarker and a data memory which stores the results of the evaluation and additional data. During a first examination, a quantity result of the biomarkers is determined and stored in the data memory. During a follow-up examination, at least one previous item of the result and additional data from the first examination stored in the data memory are used for determining a quantitative change in the biomarker.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: May 19, 2020
    Assignee: SIEMENS HEALTHCARE GMBH
    Inventors: Björn Heismann, Arne Hengerer, Sebastian Schmidt
  • Patent number: 10647692
    Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein Q is and A, R1, m, X1, X2, X3, X4, Y1, Y2 and Y3 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 12, 2020
    Assignee: FMC Corporation
    Inventors: Wenming Zhang, Michael Alan Rossi, Kasinath Sana
  • Patent number: 10633446
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: April 28, 2020
    Assignees: INSERM (Institut National de la Santéet de la Recherche Medicale), Institut Jean Paoli & Irene Calmettes, Universitéd'Aix-Marseille, Universite Claude Bernerd—Lyon }, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 10597426
    Abstract: The invention discloses a polypeptide compound and a preparation method and application thereof. The polypeptide compound has a structural formula as follows: (XAXBXCXDXE-X)2KY, or {(XAXBXCXDXE-X)2K}2KY, or {({XAXBXCXDXE-X}2K)2K}2KY, where, XA is a polar amino acid molecule, XB and XE are alkaline amino acid molecules (the same or different), XC and XD are non-polar amino acid molecules (the same or different), K is lysine (Lys, K), and X and Y are null, or any one or more amino acid or chemical groups. The polypeptide compound provided in the invention has an effect of enhancing the immune function of a body and has an application potential of being developed into a clinical medicine capable of enhancing the immune function of a body.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 24, 2020
    Assignees: BEIJING COISLITONG INDUSTRIAL CO., LTD.
    Inventor: Su Han
  • Patent number: 10549578
    Abstract: A hub for bicycles with a hub shell rotatably supported relative to a hub axle by roller bearings and a rotor rotatably supported relative to the hub axle by at least two rotor bearings and with a freewheel device with two interacting freewheel components namely, a hub-side freewheel component and a rotor-side freewheel component. The two freewheel components are movable relative to one another in the axial direction between a freewheel position and an intermeshing engaging position in which a driving torque can be transmitted. The hub-side freewheel component is compact in configuration and a hub bearing to rotatably support the hub shell is integrated and configured therein. An outer ring of the hub bearing is configured in an axial body section of the hub-side freewheel component. A sealing unit protects the interior of the hub bearing from the entry of dirt and water.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: February 4, 2020
    Assignee: DT SWISS INC.
    Inventors: Martin Walthert, Stefan Spahr
  • Patent number: 10472418
    Abstract: A use of prevention or treatment of lung cancer including an antibody specifically recognizing CD66c in lung cancer or its antigen-binding fragment and a chemotherapeutic agent is provided.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: November 12, 2019
    Assignee: Dinona
    Inventors: Kwon Pyo Hong, Mi Hyang Shin, Sangsoon Yoon, Gil Yong Ji, Yoo Ri Moon
  • Patent number: 10457733
    Abstract: The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: October 29, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe, Yanping Xiao, Loise Francisco, Rosemarie Dekruyff, Dale Umetsu
  • Patent number: 10442846
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 15, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Patent number: 10434213
    Abstract: Provided herein are keratin compositions (e.g., keratin gels, scaffolds, particulates, and the like) including a compound of interest, useful for release and/or delivery of the compound of interest (e.g., in vivo or in vitro). In some embodiments, the composition is a composition formulated for controlled release of the compound of interest.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: October 8, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: Mark E. Van Dyke, Justin M. Saul, Thomas L. Smith, Roche de Guzman
  • Patent number: 10407507
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 10, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Patent number: 10398774
    Abstract: The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: September 3, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Bruno Robert, Christel Larbouret, Pierre Martineau, Marie-Alix Poul
  • Patent number: 10401363
    Abstract: The invention relates to the use of the monoclonal antibody NILO1 for the diagnosis, treatment and/or prevention of brain tumors and lesions. Particularly, the invention relates to methods for the diagnosis of brain tumors and brain lesions in which cells marked with said antibody, or with immunologically active fragments thereof, are detected. The invention also relates to the use of said monoclonal antibody, or immunologically active fragments thereof, as a medicament for the treatment and/or prevention of brain tumors and brain lesions. In a preferred embodiment of the invention, the monoclonal antibody NILO1, or its immunologically active fragments, are humanized.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: September 3, 2019
    Assignees: ALTHIA HEALTH, S.L., CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: Augusto Silva González, José Alberto García Sanz
  • Patent number: 10391169
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: August 27, 2019
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, John A. Latham, Brian R. Kovacevich, Jeffrey T. L. Smith, Mark Litton, Randall Schatzman
  • Patent number: 10358494
    Abstract: Disclosed herein are chimeric antigen receptors (CAR) that can specifically recognize tumor-associated antigens (TAA) on multiple myeloma (MM) cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with MM that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 23, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Jianhua Yu, Craig Hofmeister, Jianhong Chu
  • Patent number: 10314889
    Abstract: This disclosure relates to compositions of isolated polypeptides and methods of their use for the treatment and prevention of disease or disease symptoms associated with MARCKS phosphorylation and/or dissociation from the cell membrane, including but not limited to allergic inflammation, asthma, chronic bronchitis, COPD, infection, hyper-reactivity, cystic fibrosis, ulcerative colitis, Crohn's disease, irritable bowel syndrome, rosacea, eczema, psoriasis, acne, arthritis, rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: June 11, 2019
    Assignee: The Regents of the University of California
    Inventors: Reen Wu, Ching-Hsien Chen, Chen-Chen Lee
  • Patent number: 10287344
    Abstract: This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: May 14, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Svetomir N. Markovic
  • Patent number: 10273294
    Abstract: Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90? and methods of using the same to treat HIF-1?-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP (SEQ ID NO: 1) in Hsp90? or VKHFSVEGQ (SEQ ID NO: 2) in Hsp90?.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: April 30, 2019
    Assignee: University of Southern California
    Inventors: Wei Li, David Woodley, Mei Chen, Divya Sahu, Hangming Dong, Mengchen Zou
  • Patent number: 10201554
    Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: February 12, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Patent number: 10172942
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: January 8, 2019
    Assignee: Pfizer Inc.
    Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra
  • Patent number: 10131933
    Abstract: The present invention relates to materials and methods suitable for determining the presence or amount of Botulinum toxin (BoNT) in a test sample by means of a luminescence assay in which the substrate peptide is composed of: an amino acid sequence susceptible to proteolytic cleavage by BoNT, an amino acid sequence corresponding to a reporter domain encoding a fluorescent or bioluminescent polypeptide, and a tag suitable for attaching the substrate peptide to a suitable support, preferably by covalent bond.
    Type: Grant
    Filed: September 3, 2012
    Date of Patent: November 20, 2018
    Assignee: Albert-Ludwigs-Universitaet Freiburg
    Inventors: Gregory Stevens, Michael Krueger, Andrea Zgaga-Griesz, Gerald Urban, Dalice Silver
  • Patent number: 10114030
    Abstract: Provided are a detection agent for detecting hydroxy vitamin D, preparation method thereof, and use thereof in 25-hydroxy vitamin D immunological detection. The detection agent comprises a conjugate formed by a 25-hydroxy vitamin D antigen derivative and protein carrier, and magnetic spheres coated by the conjugate. Also provided is a 25-hydroxy vitamin D detection kit comprising the detection agent.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: October 30, 2018
    Assignee: SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD
    Inventors: Wei Rao, Tinghua Li, Kai Du, Jinyun Yuan, Kai Luo, Huiling Yu
  • Patent number: 10059773
    Abstract: Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: August 28, 2018
    Assignee: GMAX BIOPHARM LLC.
    Inventors: Cheng Zhang, Shuqian Jing, Hua Zhang, Xiaofeng Wang, Chenjiang Yao